As Genfit deals and Conatus folds, Nash plays on
A China licensing deal from Genfit and the collapse of Conatus provide the latest news from the closely watched Nash space, which nervously awaits the next wave of…
EASL 2019 preview – Viking and Spring Bank abstracts pique early interest
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Upcoming events – Dermira awaits eczema results and Conatus gets another bash at Nash
Dermira hopes that lebrikizumab can beat Dupixent, while Conatus tries to overcome an earlier Nash setback.
Gilead’s first big Nash bash ends in the trash
The failure of the Stellar-4 study of selonsertib is a big blow for Gilead, but has not dented enthusiasm for other Nash players.
Albireo comes up to IBAT in Nash
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
AASLD 2018 – Viking lands blow in early Nash skirmish
Viking’s VK2809 looks at least as good as Madrigal’s MGL-3196 in liver disease – but investors should be careful of making comparisons.
Upcoming events – Eidos and Conatus look to catch up with big pharma rivals
Trailing the leaders in amyloidosis and Nash, the respective small caps Eidos and Conatus look to mid-stage trial readouts to demonstrate their relevance.
Liver disease is set for its pivotal year
Nash, the one-time favourite therapy area for biopharma speculators, is back.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.